[6-fluoro-3-(2-trifluoromethyl-4-methanesulfonyl-phenylsulfanyl)-2-methyl-indolizin-1-yl]acetic acid ethyl ester | 1034653-63-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: [6-fluoro-3-(2-trifluoromethyl-4-methanesulfonyl-phenylsulfanyl)-2-methyl-indolizin-1-yl]acetic acid ethyl ester
• 英文别名: Ethyl 2-[6-fluoro-2-methyl-3-[4-methylsulfonyl-2-(trifluoromethyl)phenyl]sulfanylindolizin-1-yl]acetate
• CAS: 1034653-63-8
• 化学式: C₂₁H₁₉F₄NO₄S₂
• 分子量: 489.512
• InChiKey: AONPIKWNFLIXLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  98.5
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  bis(2-trifluoromethyl-4-methanesulfonyl-benzene)disulfide 、 (6-fluoro-2-methyl-indolizin-1-yl)acetic acid ethyl ester 在 磺酰氯 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 4.5h， 生成 [6-fluoro-3-(2-trifluoromethyl-4-methanesulfonyl-phenylsulfanyl)-2-methyl-indolizin-1-yl]acetic acid ethyl ester
  参考文献：
  名称：

  WO2008/74966

  摘要：

  公开号：

文献信息

• CRTH2 ANTAGONISTS
  申请人：Hynd George

  公开号：US20100010034A1

  公开（公告）日：2010-01-14

  The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(6-fluoroquinolin-2-yl-methyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-bromophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, and [3-(4-cyclopropylsulfamoylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid.

  以下化合物是CRTH2拮抗剂，可用于呼吸系统疾病的治疗：[3-(2,4-二氯苯基硫酰基)-6-氟-2-甲基吲唑啉-1-基]乙酸，[6-氟-3-(2-氟-4-甲磺酰基苯基硫酰基)-2-甲基吲唑啉-1-基]乙酸，[6-氟-3-(4-甲磺酰基-2-三氟甲基苯基硫酰基)-2-甲基吲唑啉-1-基]乙酸，(R)-2-[6-氟-3-(4-甲磺酰基苯基硫酰基)-2-甲基吲唑啉-1-基]丙酸，[3-(4-乙烷磺酰基苯基硫酰基)-6-氟-2-甲基吲唑啉-1-基]乙酸，(S)-2-[6-氟-3-(4-甲磺酰基苯基硫酰基)-2-甲基吲唑啉-1-基]丙酸，[乙烷磺酰氨基苯并磺酰基)-6-氟-2-甲基吲唑啉-1-基]乙酸，[7-氯-6-氟-3-(4-甲磺酰基苯基硫酰基)-2-甲基吲唑啉-1-基]乙酸，[3-(2-氯-4-甲磺酰基苯基硫酰基)-7-氰基-2-甲基吲唑啉-1-基]乙酸，[6-氰基-3-(4-甲磺酰基苯基甲基)-2-甲基吲唑啉-1-基]乙酸，[3-(4-氯苯甲基)-7-氰基-2-甲基吲唑啉-1-基]乙酸，[6-氰基-3-(6-氟喹啉-2-基甲基)-2-甲基吲唑啉-1-基]乙酸，[6-氟-3-(4-甲氧苯基硫酰基)-2-甲基吲唑啉-1-基]乙酸，[7-氯-6-氟-3-(4-甲氧苯基硫酰基)-2-甲基吲唑啉-1-基]乙酸，[3-(4-溴苯基硫酰基)-6-氟-2-甲基吲唑啉-1-基]乙酸和[3-(4-环丙基磺酰氨基苯基硫酰基)-6-氟-2-甲基吲唑啉-1-基]乙酸。
• [EN] CRTH2 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CRTH2
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2008074966A1

  公开（公告）日：2008-06-26

  [EN] The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-bromophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, and [3-(4-cyclopropylsulfamoylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid.
  [FR] L'invention concerne les composés suivants. Ces composés sont des antagonistes de CRTH2 servant au traitement de maladies respiratoires: acide [3-(2,4-dichlorophénylsulfanyle)-6-fluoro-2-méthylindolizine-1 -yl]-acétique, acide [6-fluoro-3- (2-fluoro-4-méthanesulfonylphénylsulfanyle)-2-méthylindolizine-1 -yl]-acétique, acide [6- fluoro-3-(4-méthanesulfonyl-2-trifluorométhylphénylsulfanyle)-2-méthylindolizine-1-yl]-acétique, acide (R)-2-[6-fluoro-3-(4-méthanesulfonylphénylsulfanyle)-2-méthylindolizine-1-yl]-propionique, acide [3-(4-éthanesulfonylphénylsulfanyle)-6-fluoro-2-méthylindolizine-1-yl]-acétique, acide (S)-2-[6-fluoro-3-(4-méthanesulfonylphénylsulfanyle)-2-méthylindolizine-1-yl]-propionique, acide [( éthanesulfonylaminobenzènesulfonyle)-6-fluoro-2-méthylindolizine-1-yl]-acétique, acide [7-chloro-6-fluoro-3-(4-méthanesulfonylphénylsulfanyle)-2-méthylindolizine-1-yl]-acétique, acide [3-(2-chloro-4-méthanesulfonylphénylsulfanyle)-7-cyano-2-méthylindolizine-1-yl]-acétique, acide [6-cyano-3-(4-méthanesulfonylbenzyle)-2-méthylindolizine-1-yl]-acétique, acide [3-(4-chlorobenzyle)-7-cyano-2-méthylindolizine-1-yl]-acétique, acide [6-cyano-3-(6-fluoroquinoline-2-yl-méthyle)-2-méthylindolizine-1-yl]-acétique, acide [6-fluoro-3-(4-méthoxyphénylsulfanyle)-2-méthylindolizine-1-yl]-acétique, acide [7- chloro-6-fluoro-3-(4-méthoxyphénylsulfanyle)-2-méthylindolizine-1-yl]-acétique, acide [3-(4- bromophénylsulfanyle)-6-fluoro-2-méthylindolizine-1-yl]-acétique, et acide [3-(4- cyclopropylsulfamoylphénylsulfanyle)-6-fluoro-2-méthylindolizine-1-yl]-acétique.